H.C. Wainwright Says Targeted Oncology Therapies "Gives An Edge" To Tempest Therapeutics

  • H.C. Wainwright has initiated coverage of Tempest Therapeutics Inc TPST with a Buy rating and $51 price target, seeing an upside potential of over 100%. 
  • A strategic portfolio of targeted therapies in oncology "gives Tempest an edge," analyst Joseph Pantginis tells investors in a research note. 
  • According to him, Tempest sets itself apart from other companies in the immuno-oncology space by shifting its focus to innovative targets and mechanisms.
  • Recently, Tempest began trading on the NASDAQ through a reverse merger with Millendo Therapeutics.
  • Sam Whiting, chief medical officer, will participate in a webcast panel titled "Developing Therapies for the Next Immuno-Oncology Targets" at the William Blair 2021 Biotech Focus Conference tomorrow.
  • Price Action: TPST shares are up 5.42% at $25.50 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechNewsHealth CarePrice TargetInitiationAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!